Board Meeting Details

The Board of Directors meeting was held on Thursday, August 13, 2026, at the company's Registered Office in Mumbai. The meeting commenced at 4:30 PM and concluded at 5:30 PM. The Board approved:

  • The Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
  • The press release on the Un-audited Financial Results for the June 2026 quarter

Key Financial Highlights (Consolidated)

Quarterly Performance (Q1 FY27 vs Q1 FY26 vs Q4 FY26)

| Metric | Q1 FY27 | Q1 FY26 | YoY Change | Q4 FY26 | QoQ Change |

| Revenue from Operations | ₹33.11 crore | ₹22.63 crore | +46.3% | - | - |

| Profit After Tax (PAT) | ₹1.42 crore | ₹1.16 crore | +22.6% | ₹0.56 crore | +150.8% |

| Earnings Per Share (EPS) | ₹0.29 | ₹0.24 | +20.8% | ₹0.12 | +141.7% |

Consolidated Financial Results Detail (₹ in Lakhs)

Income:

  • Revenue from operations: 3310.90
  • Other Income: 65.25
  • Total Income: 3376.15

Expenses:

  • Purchases of stock-in-trade: 3190.49
  • Changes in inventories: -34.52
  • Finance costs: 0.26
  • Employee benefits expense: 8.63
  • Depreciation and amortization expense: 0.80
  • Other expenses: 68.88
  • Total expenses: 3234.53

Profitability:

  • Profit before tax: 141.62
  • Total tax expense: 0.00
  • Profit for the period: 141.62
  • Total Comprehensive Income: 141.62

Capital Structure:

  • Paid up Equity Share Capital (Face value ₹1 each): 486.72

Standalone Financial Results (₹ in Lakhs)

The company also reported standalone results:

  • Revenue from operations: 2406.66
  • Total Income: 2471.91
  • Profit before tax: 119.94
  • Profit for the period: 119.94
  • EPS: ₹0.25 (Basic and Diluted)

Management Commentary

Naveenakumar Kunjaru, Managing Director, stated: "Q1 FY27 reflects continued progress in building a scalable consumer healthcare platform. The 46.3% YoY revenue growth demonstrates underlying demand strength, while the 150.8% QoQ increase in PAT underscores improved operating leverage and cost discipline. Our focus remains on evidence-based product innovation, deeper penetration in Tier 2/3 markets, and selective international expansion."

Growth Strategy

The company is executing a multi-pillar strategy:

  • Product & R&D: Broadening portfolio across preventive care and nutrition segments
  • Distribution & Geography: Strengthening pan-India reach via offline and online channels; evaluating export opportunities in Middle East (UAE) and South Asia
  • Operational Efficiency: Optimizing channel mix, supply chain, and cost structures to support margin expansion

Subsidiary Information

The consolidated results include the following subsidiaries:

1. Aayush Healthscience Private Limited

2. Aayush Worldwide Private Limited

3. Aayush Labs Private Limited

4. Aayush Ventures Private Limited

5. Aayush International Private Limited

Auditor Review

A. Raghavendra Rao & Associates, Chartered Accountants (Firm Reg No: 003324), conducted a limited review of both standalone and consolidated financial results. Their review concluded that nothing came to their attention causing them to believe that the financial statements are not prepared in all material respects in accordance with applicable accounting standards and SEBI regulations.

Additional Notes

1. The financial results were reviewed by the Audit Committee and approved by the Board of Directors

2. Results prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 (Ind AS)

3. Company operates in a single primary business segment (disclosure under Ind AS 108 not applicable)

4. Provision for taxes, if any, shall be made at year-end

5. Previous period figures have been re-grouped and re-classified where necessary